INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

Similar documents
Insulin Initiation and Intensification. Disclosure. Objectives

Learning Objectives. Are you ready for more insulin formulations?

New Therapies for Diabetes Management: Hope or Headache?

Individualizing Care for Patients with Type 2 Diabetes

The Management of Diabetes in Primary Care Kelly Krawtz, PharmD, BCPS, BCACP

INSULIN 101: When, How and What

Mixed Insulins Pick Me

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Intensification of Diabetic Therapy. Case studies

Type 2 Diabetes Mellitus Insulin Therapy 2012

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Advances in Diabetes Care Technologies

Physiology of Normoglycemia

Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

Incorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital

How they work and when to take them. Diabetes Medications

Inpatient Glycemic Management:

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Using Insulin in the Primary Care Setting: Interactive Cases

Rebecca Newberry APRN MS CDE

7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine

Making Sense of New DM Therapies and Technologies

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

Disclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2

GLP-1 receptor agonists for type 2 diabetes currently available in the U.S.

Learning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C

What s New in Type 2 Diabetes? 2018 Diabetes Updates

BEST 4 Diabetes. Optimisation of insulin module

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

BEST 4 Diabetes. Optimisation of insulin module

2018 Diabetes Summit Managing Diabetes: An Art and a Science

Advances in Diabetes Care Technologies

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol

Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?

Insulin Prior Authorization with optional Quantity Limit Program Summary

1. Continuous Glucose Monitoring

CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Today s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures

Diabetes Management: A diagnostic perspective

Application of the Diabetes Algorithm to a Patient

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical

Diabetes Meds Update Disclaimer and Important Info. Objectives. Page 1. Copyright , Diabetes Education Services

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)

Basal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

Technology in Diabetes Care: Emerging Level

Initiating Injectables in Type 2 Diabetes. Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital

Newer Therapies for Type 2 Diabetes

Diabetes: We ve Come a Long Way, Baby! Amy Wachter, MD Christiana Care Endocrinology March 22, 2018

CASE A2 Managing Between-meal Hypoglycemia

Making the Most of Continuous Glucose Monitoring

NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP

Insulin Management. By Susan Henry Diabetes Specialist Nurse

How I use the latest technology to investigate and treat a person with Type 1 Diabetes. Dr Pratik Choudhary

The York Diabetes Care Model

LET S TALK INSULIN THE BASICS

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care

Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference

A Practical Approach to the Use of Diabetes Medications

Clinical Practice Guidelines

STEP THERAPY CRITERIA

8/21/2017 UNRAVELING THE CROWED INSULIN SCENE. A Practical Overview of Insulin Focusing on New Insulin Preparations

Updates in Diabetes Technology

Diabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:

NEW DIABETES CARE MEDICATIONS

!"#$%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!(((

The Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center

Objectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17

Complete this CE activity online at ProCE.com/InsulinPart2

Very Practical Tips for Managing Type 2 Diabetes

Rhonda Eustice, PharmD, CDE. Will Power lasts about two weeks and is soluble in alcohol. Mark Twain

The ABCs of MDI: Gaining a working knowledge of Multiple Daily Injection insulin therapy. Today s Presenter

Pediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services

DIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT

Update on Insulin-based Agents for T2D

Achieving and maintaining good glycemic control is an

Technology in Diabetes Management Irl B. Hirsch, MD University of Washington

Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy

Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)

There have been important changes in diabetes care which may not be covered in undergraduate textbooks.

The Realities of Technology in Type 1 Diabetes

Insulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

Diabetes Management: Current High Tech Innovations

Starting and Helping People with Type 2 Diabetes on Insulin

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection

Transcription:

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018

DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott

T1DM: DESTRUCTION OF THE PANCREAS Type 1 Diabetes is caused by the autoimmune destruction of insulin producing ß-cells Antigen TCR T Cell T Cell ß-cells T-cells mediated killing of ß-cells

T2DM: RESISTANCE TO INSULIN Food Intake Fat cells Muscle cells Liver Carbohydrate absorbed Insulin Elevated Blood Glucose Pancreas

INSULIN ACTION Glucose uptake Lipolysis Fat storage Fat cells Muscle cells Liver Glucose production Glucose storage Carbohydrate absorbed Insulin Elevated Blood Glucose Pancreas

INSULIN RESISTANCE Fat cells Muscle cells Liver Carbohydrate absorbed Insulin Elevated Blood Glucose Pancreas

CASE #1 48 year old man with Type 2 DM x 12 years. Current DM meds Metformin 1000 mg BID Sitagliptin 100 mg QD Glipizide 10 mg BID On ACE-I for Hypertension and Statin for elevated Cholesterol

CASE #1 PE: Obese, 5 10, 245 lbs. BMI 35.15 PE otherwise unremarkable HbA1C 8.7 % Fasting BG levels between 160-190 What is the next step for DM management?

BARRIERS TO STARTING INSULIN Fear of needles Fear of hypoglycemia No time to learn about insulin Concerns about side effects of insulin History of family member that was on insulin and then Feeling like failure in terms of diabetes

INSULIN DELIVERY DEVICES

STARTING BASAL INSULIN AACE Guidelines: Pick a starting dose for basal insulin A1c < 8 % 14-28 units A1c > 8 % 28-43 units I often start at either 10 or 20 units or based on weight for morbidly obese patients otherwise it takes long to titrate

STARTING BASAL INSULIN Titration: Increase insulin by 2 units 2 x per week (pick days) until fasting blood glucose levels are to goal Decrease by 2 units if hypoglycemia Goal Blood Sugar: Generally 90-130 mg/dl Higher risk of hypoglycemia 100-150 mg/dl Max dose insulin: 40 units is a reasonable start Allows patients to be comfortable increasing dose

STARTING BASAL INSULIN Start insulin Glargine 20 units between 9-11 PM Check FSBG levels every morning Goal fasting BG: 90-130 mg/dl Every Wed and Sat review your blood glucose levels and if not to goal, increase Glargine dose by 2 units (example increase from 20 to 22 units daily) Once you reach Glargine 40 units please contact provider

CASE #1 CONT. Started on Glargine 20 units Goal fasting BG 90-130 mg/dl Titrate 2 x per week Follow up appointment in 1 month Glargine increased to 32 units Fasting BG usually around 130-140 mg/dl Had one episode of low BG with symptoms, checked FSBG and it was 82 mg/dl Stopped increasing his dose after that low

CASE #2 82 year old man with Type 2 Diabetes for 30 years. He lives by himself and is very worried about low blood glucose levels Current DM meds: Metformin 1000 mg BID Degludec 24 units at night Empagliflozin 10 mg QD HbA1c of 8.4 % at appointment today. Checks FSBG once per day. Fasting range 98-164 mg/dl What are your options for next steps?

CASE #2 Options include: GLP1-RA SU Prandial Insulin DPP4 inhibitor TZD If hypoglycemia is his main concern, what options would you consider?

CASE #2 CONT. Decided to start on a GLP1 RA Options: Once daily injection (Liraglutide/Victoza) Once weekly injection (Duglaglutide / Trulicity, Exenatide/Bydureon, Semaglutide / Ozempic) Combination (Soliqua 100/33 Glargine and Lixisenatide or Xultrophy 100/3.6 Degludec and Liraglutide)

CASE #3 62 year old woman with a history type 2 DM for 14 years She struggles with her diet and finds the higher carbohydrate options easiest while at work Current DM meds: Toujeo (U300 Glargine) 56 units Dulaglitide/Trulicity 1.5 mg weekly Canagliflozin / Invokana 300 mg QD Repaglinide / Prandin 1 mg 1-2 tabs before meals

Case #3 cont. HbA1c 10.0 %!! Forgot her BG meter, but does try to check her FSBG 1-2 times per week fasting Reports good BG levels, usually around 100-120 mg/dl in the morning Admits, she does miss the Repaglinide / Prandin several times per week

Case #3 cont. CGM placed and she returns in 2 weeks with data

INSULIN OPTIONS

BASAL / BOLUS INSULIN

BASAL/BOLUS INSULIN Basal Insulin Long acting insulin to help lower fasting and between meal BG levels Bolus Insulin Prandial Insulin (meal time) Short acting insulin taken before a meal to prevent a post prandial spike Correctional Insulin Short acting insulin, extra insulin taken to correct a high BG level

CASE #3 CONT. Will start short acting insulin prior to each meal Current Basal insulin dose is 54 units. But her BG is dropping 100-200 mg/dl overnight Decrease Basal Insulin to 40 units Start prandial insulin with meal(s)

CASE #3 Basal plus one: Start 10 % of basal or 5 units with one meals Basal / Bolus: Start 50 % basal and 50 % bolus Total daily insulin dose: 0.3-0.5 units/kg

CASE #3 CONT Decrease Toujeo dose to 40 units Start Lispro 10 units with each meal Encouraged her to keep CHO consistent around 45-60 gm. per meal Add correction insulin if BG above 150 per sliding scale

CASE #3 CONT. Blood Sugar: Insulin Dose: <70 No insulin, 15 gm of CHO and repeat 70-150 10 units 151-200 12 units 201-250 14 units 251-300 16 units >300 18 units

CASE #3 She does not like carrying her Sliding Scale around, how else can she determine her insulin doses? CHO counting working with a dietician, patient learns to count CHO and determine insulin dose based on CHO content of the meal example: 1 unit of insulin per 5 gm. of CHO Correction or sensitivity factor determine decrease in BG per unit of insulin example: 1 unit per 25 mg/dl above target of 150 mg/dl

CASE #4 67 year old man with Type 2 DM x 22 years presents to your office. His complications include nephropathy and neuropathy Rx History: He has been on insulin for over 15 years. No oral agents due to renal disease and intolerance Current RX: Glargine 80 units Lispro 25 units with meals

CONCENTRATED INSULIN Is he a good candidate for a concentrated insulin? What options are available for concentrated Insulin's?

CONCENTRATED INSULIN Candidates: Insulin resistance: on medications such as steroids Genetic forms of insulin resistance On more than 100 units per day of insulin Presence of insulin antibodies Type 1 DM with obesity or overweight

CONCENTRATED INSULIN OPTIONS U500 syringe and vial remember dose is 5 X amount seen on the insulin syringe U500 Pen dose is in units U300 Glargine (Toujeo) Solostar pen U200 Degludec (Tresiba) - Flexpen U200 Lispro (Humalog) Kwik pen

INTEGRATED PUMP/CGM SYSTEMS Minimum 670G is the first hybrid closed loop system Data from the CGM is transmitted to the pump and the basal rate is adjusted Patient must still enter CHO and corrections More integrated systems to come in the next 1-2 years

CASE #4 CONT. Started on U-300 Glargine and U-200 Humalog with meals Advantages: Smaller injection volume (more comfortable) Pens last longer (and less waste) Potentially less risk of hypoglycemia (especially overnight) Less time dependent (any time of day dosing)

CASE #5 24 year old woman with Type 1 Diabetes working at a start up just moved to the area DM diagnosed at age 9. No complications HbA1c 8.2 % Current insulin doses: Degludec: 12 units AM, 8 units PM Lispro: 1 unit per 14 gm of carbohydrate 1 unit per 20 mg/dl above target of 120 mg/dl She is interested in learning more about technology for Diabetes what are her options?

TECHNOLOGY Insulin Delivery Systems Blood glucose monitoring Meters Continuous Glucose Sensors

CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) Catheter is placed subcutaneously and connected to an electronic pump. Pump delivers low levels of basal rate short acting insulin (rates can vary during the day). Patient can give boluses for meals and corrections for high blood glucose levels.

REAL TIME CONTINUOUS GLUCOSE SENSORS Subcutaneous catheter inserted every 7-10 days. Interstitial fluid BG measurement every 5 minutes. Alarms can be set for highs and lows. Currently available CGMs: Medtronic Minimed Dexcom G5 (G6 any day now) Abbott Freestyle Libre

REAL TIME CONTINUOUS GLUCOSE SENSORS

CASE #5 CONT. Patients decides to start on a CGM to help warn her about hypoglycemia Finds that she was having nocturnal hypoglycemia and rebound fasting high BG levels Decreased her Basal Insulin Discovered a lot of after meal highs, needs to adjust the timing of her meal time insulin She is considering her options for a closed loop system in the future

Thank you! Contact information: email: Jaiwantrangi@hotmail.com Office: 530-677-0700